There are 2789 resources available
669P - Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study
Presenter: Rustem Gafanov
Session: ePoster Display
670P - Cabozantinib associated with concomitant radiotherapy or a bone targeted agent (multimodal approach, results from the CABOREAL study post-hoc analysis)
Presenter: Marine Gross-Goupil
Session: ePoster Display
633P - Mutational landscape differences between young-onset and older-onset prostate cancer patients
Presenter: Yong Wang
Session: ePoster Display
635P - Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer
Presenter: Hui-Ming Lin
Session: ePoster Display
636P - A comparative analysis of prostate cancer short-term recurrence risk forecast performance between 8-gene signature and commercial panels
Presenter: Jinan Guo
Session: ePoster Display
676P - CABOPRE: A phase II study of cabozantinib (cabo) prior cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)
Presenter: Guillermo De Velasco
Session: ePoster Display
677P - Immunotherapy vs sunitinib as first-line treatment for advanced renal cell carcinoma in favourable risk patients: A meta-analysis of randomized clinical trials
Presenter: Ray Manneh Kopp
Session: ePoster Display
678P - Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICI)
Presenter: Andrew Hahn
Session: ePoster Display